^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

mTOR (Mechanistic target of rapamycin kinase)

i
Other names: mTOR, Mechanistic Target Of Rapamycin Kinase, Mammalian Target Of Rapamycin, Rapamycin And FKBP12 Target 1, FK506-Binding Protein 12-Rapamycin Complex-Associated Protein 1, Mechanistic Target Of Rapamycin (Serine/Threonine Kinase), FK506 Binding Protein 12-Rapamycin Associated Protein 2, FKBP12-Rapamycin Complex-Associated Protein 1, Serine/Threonine-Protein Kinase MTOR, Rapamycin Associated Protein FRAP2, FKBP-Rapamycin Associated Protein, Mechanistic Target Of Rapamycin, Rapamycin Target Protein 1, FRAP1, FRAP2, RAFT1, RAPT1, FRAP
5d
Carvedilol attenuates doxorubicin-evoked renal toxicity in rats: The role of PI3K/AKT/mTOR, Nrf2/HO-1 and Bax/Bcl2 signals. (PubMed, Tissue Cell)
Such findings were supported by renal histological features improvement. In conclusion, CAR counteracted the renal damage induced by DOX via suppressing oxidative stress, inflammatory response, and apoptosis through downregulation of PI3K/Akt/mTOR and Bax/Bcl2 and upregulation of Nrf2/HO-1 signals.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • mTOR (Mechanistic target of rapamycin kinase) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • KIM1 (Kidney injury molecule 1) • PI3K (Phosphoinositide 3-kinases)
|
doxorubicin hydrochloride
10d
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System (clinicaltrials.gov)
P2, N=86, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Initiation date: Mar 2026 --> Oct 2026
Enrollment open • Trial initiation date
|
mTOR (Mechanistic target of rapamycin kinase)
|
Erbitux (cetuximab) • Rybrevant (amivantamab-vmjw)
10d
Utility of Next-Generation Sequencing in Renal Neoplasia, Including Tumors With Clear Cytoplasm and Rare Phenotypes (ELOC/MITF Alterations and Mismatch Repair Deficiency). (PubMed, Mayo Clin Proc)
Next-generation sequencing-based molecular profiling had clinical utility in two-thirds of patients, and the greatest benefit was within the broad category of ccRCN. Our results suggest that GPNMB expression was helpful in separating ELOC-RCCfms from M/TSC-RCCfms. Other benefits of NGS include subtyping high-grade RCC/RCC type not otherwise specified and identification of rare phenotypes.
Journal • Next-generation sequencing • Mismatch repair
|
mTOR (Mechanistic target of rapamycin kinase) • TSC2 (TSC complex subunit 2) • TSC1 (TSC complex subunit 1) • CA9 (Carbonic anhydrase 9) • GPNMB (Glycoprotein Nmb) • MITF (Melanocyte Inducing Transcription Factor)
10d
Sexual Dimorphism in the Initial Apoptotic Switch During MASH Progression in Mice. (PubMed, Int J Mol Sci)
The expression of ATP1A1, survivin, and SMAC did not differ by sex or diet, although an upregulation trend in both ATP1A1 and survivin was noted in the male-HFD group. There is sexual dimorphism in the response to HFD during the transition from senescence to the apoptosis-first apoptotic switch in MASH progression.
Preclinical • Journal
|
TP53 (Tumor protein P53) • mTOR (Mechanistic target of rapamycin kinase) • BIRC5 (Baculoviral IAP repeat containing 5) • GRB2 (Growth Factor Receptor Bound Protein 2) • ATP1A1 (ATPase Na+/K+ Transporting Subunit Alpha 1)
11d
Effect of the G-Protein-Coupled Receptor T2R14 on Proliferation and Cell Population Growth in Oral Cancer Cells. (PubMed, Cells)
This study showed that TAS2R14 knockout in oral cancer cells significantly decreased calcium mobilization, increased cell numbers, colony formation, the proliferation marker proliferating cell nuclear antigen, and the phosphorylation of mechanistic target of rapamycin, but did not affect cell viability...Therefore, T2R14 downregulation increased oral cancer CPG, suggesting a tumor-suppressor-like role. The study's findings could improve our understanding of T2R14 mechanisms and help develop strategies to advance oral cancer treatment by targeting T2R14.
Journal
|
mTOR (Mechanistic target of rapamycin kinase) • PCNA (Proliferating cell nuclear antigen)
|
sirolimus
11d
Intracellular Signaling Pathways for Erythropoietin-Induced Cell Proliferation in Primary Cultured Hepatocytes. (PubMed, Biol Pharm Bull)
In contrast, intracellular Ca2+ concentration and activated Ras were transiently increased in hepatocytes after EPO stimulation, and EPO-induced activated Ras was significantly suppressed by the specific PKC inhibitor GF109203X. These results indicate that EPO engages the JAK2/PLC/PKC-Ca2+ signaling cascade, leading to the sequential activation of Ras, C-Raf, and ERK2, ultimately promoting hepatocyte proliferation in vitro.
Journal
|
mTOR (Mechanistic target of rapamycin kinase)
23d
mTOR Modulation Affects Galectin-1 Expression in KMT2A-rearranged Acute Lymphoblastic Leukemia Cells. (PubMed, Anticancer Res)
Targeting mTOR signaling contributes to the regulation of Galectin-1 immune checkpoint activity in KMT2Ar-ALL. Inhibition of mTOR may represent a potential therapeutic strategy to overcome immune evasion in this leukemia subtype.
Journal • IO biomarker
|
mTOR (Mechanistic target of rapamycin kinase) • KMT2A (Lysine Methyltransferase 2A) • LGALS1 (Galectin 1)
|
everolimus
24d
Genomic Landscape of Thymic Carcinoma: A Large-Scale Analysis of Somatic Mutations, Demographic Disparities, and Metastatic Drivers from the AACR Project GENIE® Cohort. (PubMed, Curr Issues Mol Biol)
The identification of sex-associated and race-associated mutational patterns, together with the enrichment of MTOR alterations in recurrent and metastatic disease, highlights biologically plausible mechanisms of progression and potential therapeutic vulnerabilities. These findings support the value of comprehensive genomic profiling in TC and emphasize the need for prospective, multi-omic studies to validate these observations and guide the development of more personalized treatment strategies.
Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • mTOR (Mechanistic target of rapamycin kinase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • STAT5B (Signal Transducer And Activator Of Transcription 5B)
|
CDKN2A deletion
24d
Radiomics-based gradient boosting model on contrast-enhanced MRI for non-invasive prediction of epidermal growth factor receptor expression and therapeutic response to EGFR-targeted antibody-drug conjugates in high-grade glioma organoid models. (PubMed, J Transl Med)
EGF/EGFR expression is associated with immunosuppressive microenvironments and adverse outcomes in HGG. Radiomics may provide a non-invasive approach for estimating EGFR expression, although model performance requires external validation and EGFR-ADCs showed partial inhibitory activity within the tested range, though potency remains to be defined.These findings suggest a framework into radiogenomic stratification and targeted therapy in GBM.
Journal
|
mTOR (Mechanistic target of rapamycin kinase) • CD4 (CD4 Molecule)
|
EGFR expression • EGFR positive
|
temozolomide • sirolimus
26d
Development of a machine learning model for predicting the expression of proteins associated with targeted therapy in endometrial cancer. (PubMed, Front Oncol)
Calibration curve analysis and DCA showed that the combination models were both well calibrated and clinically useful. Machine learning models integrating multi-parametric MRI radiomics and clinicopathological features can be a potential tool for predicting PTEN, PIK3CA, and mTOR expression status in EC patients.
Journal
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • mTOR (Mechanistic target of rapamycin kinase)
26d
Polyphyllin II Triggers Pyroptosis in Hepatocellular Carcinoma via Modulation of the ROS/NLRP3/Caspase-1/GSDMD Axis. (PubMed, Antioxidants (Basel))
The Western blot results of tumor tissues revealed that the pyroptosis effect of PPII on liver cancer was associated with the activation of the NLRP3/Caspase1/GSDMD pathway, which upregulates the expression of NLRP3, Cleaved-Caspase 1, GSDMD-N, IL-1β, and IL-18 proteins and downregulates the expression of pro-Caspase 1 and GSDMD proteins. In summary, our findings revealed the pyroptosis effect and mechanism of PPII in HCC cells in vitro and in vivo, suggesting that PPII may be used as a potential pyroptosis inducer for HCC treatment in the future.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • mTOR (Mechanistic target of rapamycin kinase) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL18 (Interleukin 18) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3) • IFNB1 (Interferon Beta 1) • CASP1 (Caspase 1) • GSDMD (Gasdermin D)
|
PD-L1 expression
26d
ANXA2P2 and PA2G4P4 Pseudogenes Are Associated with the Response to Ionizing Radiation and Could Be Used as Potential Biomarkers: In Silico Study. (PubMed, Biomedicines)
ANXA2P2 and PA2G4P4 are clinically relevant pseudogenes associated with tumor aggressiveness, immune modulation, and radiotherapy response in HNSCC. These findings support their potential utility as prognostic and predictive biomarkers and provide a rationale for further functional validation in experimental models.
Journal
|
mTOR (Mechanistic target of rapamycin kinase)